Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer

Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA.
International journal of radiation oncology, biology, physics (Impact Factor: 4.18). 11/2011; 83(1):235-42. DOI: 10.1016/j.ijrobp.2011.06.2000
Source: PubMed

ABSTRACT To define the roles of radiotherapy and chemotherapy on the risk of Grade 3+ mucositis during intensity-modulated radiation therapy (IMRT) for oropharyngeal cancer.
164 consecutive patients treated with IMRT at two institutions in nonoverlapping treatment eras were selected. All patients were treated with a dose painting approach, three dose levels, and comprehensive bilateral neck treatment under the supervision of the same radiation oncologist. Ninety-three patients received concomitant chemotherapy (cCHT) and 14 received induction chemotherapy (iCHT). Individual information of the dose received by the oral mucosa (OM) was extracted as absolute cumulative dose-volume histogram (DVH), corrected for the elapsed treatment days and reported as weekly (w) DVH. Patients were seen weekly during treatment, and peak acute toxicity equal to or greater than confluent mucositis at any point during the course of IMRT was considered the endpoint.
Overall, 129 patients (78.7%) reached the endpoint. The regions that best discriminated between patients with/without Grade 3+ mucositis were found at 10.1 Gy/w (V10.1) and 21 cc (D21), along the x-axis and y-axis of the OM-wDVH, respectively. On multivariate analysis, D21 (odds ratio [OR] = 1.016, 95% confidence interval [CI], 1.009-1.023, p < 0.001) and cCHT (OR = 4.118, 95% CI, 1.659-10.217, p = 0.002) were the only independent predictors. However, V10.1 and D21 were highly correlated (rho = 0.954, p < 0.001) and mutually interchangeable. cCHT would correspond to 88.4 cGy/w to at least 21 cc of OM.
Radiotherapy and chemotherapy act independently in determining acute mucosal toxicity; cCHT increases the risk of mucosal Grade 3 toxicity ≈4 times over radiation therapy alone, and it is equivalent to an extra ≈6.2 Gy to 21 cc of OM over a 7-week course.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To better understand the indirect effects of standard courses of radiation therapy (RT) on distant tissue toxicity, we evaluated the frequency, course, and health and economic burden of regimen-related diarrhea in a large, multinational group of patients who were being treated for cancers of the head and neck (HNC) or lung (NSCLC).
    Supportive Care Cancer 08/2014; 23(2). DOI:10.1007/s00520-014-2395-9 · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective In a new strategy, determine whether vasoconstriction and transient hypoxia of the mucosa during irradiation would prevent or suppress radiation-induced oral mucositis (OM). Study Design Topical vasoconstrictor was applied once to oral cavity; 20 min later hamsters or mice received 19-30 Gy to mucosa. OM was scored using functional assay, gross morphology, and histology of mucosal tissue over next 12-16 days. Results A single application of phenylephrine (14-136 mM) 20 min before irradiation conferred highly significant (P<0.001), dose-dependent suppression of weight loss, oral secretion, and histopathology of mucosa seen in mice treated with 0 mM phenylephrine + 19 Gy radiation. Epinephrine, norepinephrine and phenylephrine showed up to 100% radioprotective efficacy at concentrations that reflected their rank-ordered affinities for the α1 adrenergic receptor. Conclusions Phenylephrine “swish and spit” application before radiotherapy, or multiple applications during chemotherapy, may provide a simple, cost-effective strategy for suppression of OM in cancer radiotherapy, chemotherapy, and bone marrow transplant patients.
    01/2013; 117(4). DOI:10.1016/j.oooo.2013.12.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summarize functional outcomes after transoral robotic surgery (TORS) ± adjuvant therapy for oropharyngeal cancer (OPC). A systematic review was conducted. The MEDLINE database was searched (MeSH terms: TORS, pharyngeal neoplasms, oropharyngeal neoplasms). Peer-reviewed human subject papers published through December 2013 were included. Exclusion criteria were as follows: (1) case report design (n < 10), (2) review article, or (3) technical, animal, or cadaver studies. Functional outcomes extracted included feeding tube dependence, swallow examination findings, speech ratings, velopharyngeal insufficiency, pneumonia, and oral intake measures. Twelve papers comprising 441 patients with OPC treated with TORS ± adjuvant therapy were included. Feeding tube rates were the most commonly reported functional outcome. Excluding prophylactic placement, 18-39 % of patients required gastrostomy placement, typically during adjuvant therapy. Chronic gastrostomy dependence ranged from 0 to 7 % (mean follow-up 11-26 months), regardless of disease stage. Composite MD Anderson Dysphagia Inventory (MDADI) scores ranged from 65.2 to 78 (89 patients, 3 series, mean follow-up 12-13 months). Videofluoroscopic swallowing studies were not systematically reported. Incidence of postoperative pneumonia was 0-7 %. Predictors of swallowing function included baseline function, T-stage, N-stage, tongue base primary tumors, and adjuvant chemoradiation. Rates of transient hypernasality were 4-9 %. A single study suggested dose-dependent effects of adjuvant therapy (none, radiation alone, chemoradiation) on diet scores at 6 and 12 months. Crude end points of functional recovery after TORS ± adjuvant therapy suggest promising swallowing outcomes, depending on the functional measure reported.
    Archives of Oto-Rhino-Laryngology 03/2014; 272(2). DOI:10.1007/s00405-014-2985-7 · 1.61 Impact Factor


Available from
Jun 1, 2014